Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings for imiquimod vs cidofovir Response to treatment at 6 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia (2016) · Cochrane | RR 0.92 [0.73, 1.18] | 1 study · 180 participants | Moderate |
Intervention NR Overall 5‐year survival1 · women with stage I/II epithelial ovarian cancer Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer (2015) · Cochrane | no estimate extracted | 1008 participants | High |
Intervention NR Progression‐free 5‐year survival2 · women with stage I/II epithelial ovarian cancer Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer (2015) · Cochrane | no estimate extracted | 1170 participants | High |
Intervention NR Overall 10‐year3 survival · women with stage I/II epithelial ovarian cancer Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer (2015) · Cochrane | no estimate extracted | 925 participants | High |
Intervention NR Progression‐free 10‐year survival4 · women with stage I/II epithelial ovarian cancer Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer (2015) · Cochrane | no estimate extracted | 925 participants | High |
Intervention NR Adverse events · women with stage I/II epithelial ovarian cancer Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality up to 30 days · people with neutropenia or neutrophil dysfunction Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction (2015) · Cochrane | RR 0.92 [0.63, 1.36] | 7 studies · 437 participants | Very low |
Intervention NR Mortality due to infection up to 30 days · people with neutropenia or neutrophil dysfunction Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction (2015) · Cochrane | RR 0.69 [0.33, 1.44] | 6 studies · 286 participants | Very low |
Intervention NR People with localised or systemic bacterial or fungal infections ‐ low‐dose granulocyte transfusions · people with neutropenia or neutrophil dysfunction Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction (2015) · Cochrane | RR 0.84 [0.58, 1.2] | 4 studies · 204 participants | Very low |
Intervention NR People with localised or systemic bacterial or fungal infections ‐ Intermediate‐dose granulocyte transfusions · people with neutropenia or neutrophil dysfunction Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction (2015) · Cochrane | RR 0.4 [0.26, 0.63] | 4 studies · 293 participants | Low |
Intervention NR People with bacteraemia or fungaemia · people with neutropenia or neutrophil dysfunction Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction (2015) · Cochrane | RR 0.45 [0.3, 0.65] | 9 studies · 609 participants | Low |
Intervention NR People with localised bacterial or fungal infection · people with neutropenia or neutrophil dysfunction Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction (2015) · Cochrane | RR 0.75 [0.5, 1.14] | 6 studies · 296 participants | Very low |
Intervention NR People with serious adverse events · people with neutropenia or neutrophil dysfunction Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction (2015) · Cochrane | no estimate extracted | NR | No studies |
Dance/movement therapy vs standard care DepressionProfile of Moods Scale (depression subscale) and Hospital Anxiety and Depression Scale · patients with improving psychological and physical outcomes in cancer patients Dance/movement therapy for improving psychological and physical outcomes in cancer patients (2015) · Cochrane | no estimate extracted | 2 studies · 170 participants | Very low |
Dance/movement therapy vs standard care StressSymptom Checklist_90_Revised and Perceived Stress Scale · patients with improving psychological and physical outcomes in cancer patients Dance/movement therapy for improving psychological and physical outcomes in cancer patients (2015) · Cochrane | no estimate extracted | 2 studies · 170 participants | Very low |
Dance/movement therapy vs standard care FatigueProfile of Moods Scale (Fatigue subscale) and Brief Fatigue Inventory · patients with improving psychological and physical outcomes in cancer patients Dance/movement therapy for improving psychological and physical outcomes in cancer patients (2015) · Cochrane | no estimate extracted | 2 studies · 170 participants | Very low |
Dance/movement therapy vs standard care Body ImageBorscheid, Walster, Bohrnstedt Body Image Scale and The Body Image Scale · patients with improving psychological and physical outcomes in cancer patients Dance/movement therapy for improving psychological and physical outcomes in cancer patients (2015) · Cochrane | no estimate extracted | 2 studies · 68 participants | Very low |
Dance/movement therapy vs standard care AnxietyHospital Anxiety and Depression Scale and Symptom Checklist 90‐Revised · patients with improving psychological and physical outcomes in cancer patients Dance/movement therapy for improving psychological and physical outcomes in cancer patients (2015) · Cochrane | no estimate extracted | 2 studies · 170 participants | Very low |
Dance/movement therapy vs standard care CI: Confidence interval · patients with improving psychological and physical outcomes in cancer patients Dance/movement therapy for improving psychological and physical outcomes in cancer patients (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for imiquimod vs placebo Pain ‐ Any grade · women with high‐grade VIN Medical interventions for high‐grade vulval intraepithelial neoplasia (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for imiquimod vs placebo Dose reductions · women with high‐grade VIN Medical interventions for high‐grade vulval intraepithelial neoplasia (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for imiquimod vs cidofovir Pain ‐ Any grade · women with high‐grade VIN Medical interventions for high‐grade vulval intraepithelial neoplasia (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for imiquimod vs cidofovir Fatigue ‐ Any grade · women with high‐grade VIN Medical interventions for high‐grade vulval intraepithelial neoplasia (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for imiquimod vs cidofovir Headache ‐ Any grade · women with high‐grade VIN Medical interventions for high‐grade vulval intraepithelial neoplasia (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for imiquimod vs cidofovir Treatment discontinuation · women with high‐grade VIN Medical interventions for high‐grade vulval intraepithelial neoplasia (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Total pregnancy rate · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 1.29 [1.02, 1.64] | 4 studies · 38050 participants | Very low |
Intervention NR Pregnancy rate in women with intention to conceive · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 0.93 [0.8, 1.08] | 2 studies · 70 participants | Very low |
Intervention NR Conception at > 12 months · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 1.45 [0.89, 2.37] | 3 studies · 1348 participants | Very low |
Intervention NR Miscarriage rates · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 1.04 [0.9, 1.21] | 10 studies · 39504 participants | Low |
Intervention NR 1st trimester miscarriage rates · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 1.16 [0.8, 1.69] | 4 studies · 1103 participants | Low |
Intervention NR 2nd trimester miscarriage rates · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 2.6 [1.45, 4.67] | 8 studies · 2182268 participants | Low |
Intervention NR Ectopic pregnancy · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 1.89 [1.5, 2.39] | 6 studies · 38193 participants | Low |
Intervention NR TOP rates · patients with cervical intraepithelial lesions Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (2015) · Cochrane | RR 1.71 [1.31, 2.22] | 7 studies · 38208 participants | Low |
Cannabinoids vs placebo Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 2 [0.2, 21] | 2 studies · 96 participants | Low |
Cannabinoids vs other anti‐emetic agent Participant preference ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 2.8 [1.9, 4] | 9 studies · 799 participants | Low |
Cannabinoids vs other anti‐emetic agent Withdrawal any reason ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 3.5 [1.4, 9] | 1 study · 42 participants | Low |
Cannabinoids vs other anti‐emetic agent Withdrawal due to lack of efficacy ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 0.97 [0.04, 21] | 2 studies · 118 participants | Very low |
Cannabinoids vs other anti‐emetic agent Withdrawal due to adverse event ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 3.2 [1.3, 8] | 6 studies · 740 participants | Low |
Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 10 [0.61, 183] | 1 study · 37 participants | Very low |
Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 1.5 [0.69, 3.1] | 2 studies · 89 participants | Low |
Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 1.6 [0.68, 3.6] | 1 study · 37 participants | Low |
Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy Withdrawal any reason ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 1.3 [0.41, 4.2] | 1 study · 41 participants | Low |
Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy Withdrawal due to adverse event ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 7 [0.88, 55] | 2 studies · 105 participants | Very low |
Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy Withdrawal due to lack of efficacy ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 0.12 [0.01, 2] | 1 study · 41 participants | Low |
Cannabinoids vs placebo Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 5.7 [2.6, 12.6] | 3 studies · 168 participants | Low |
Cannabinoids vs placebo Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 2.9 [1.8, 4.7] | 3 studies · 288 participants | Moderate |
Cannabinoids vs placebo Participant preference ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 4.8 [1.7, 13] | 2 studies · 256 participants | Low |
Cannabinoids vs placebo Withdrawal any reason ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 0.31 [0.01, 7] | 1 study · 33 participants | Very low |
Cannabinoids vs placebo Withdrawal due to adverse event ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 6.9 [1.96, 24] | 2 studies · 276 participants | Very low |
Cannabinoids vs other anti‐emetic agent Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 1.46 [0.67, 3.15] | 5 studies · 258 participants | Low |